

Keith D Eaton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12064/publications.pdf>

Version: 2024-02-01

57
papers

9,749
citations

257450

24
h-index

175258

52
g-index

57
all docs

57
docs citations

57
times ranked

17345
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2455-2465.	27.0	6,820
2	Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3076-3083.	1.6	402
3	Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation. <i>Clinical Cancer Research</i> , 2010, 16, 5260-5268.	7.0	389
4	Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels. <i>PLoS ONE</i> , 2013, 8, e64795.	2.5	258
5	Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 56-67.	2.8	234
6	Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1415-1421.	1.6	180
7	Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, e137-e138.	8.6	138
8	Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. <i>Science Signaling</i> , 2019, 12, .	3.6	130
9	A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 837-845.	7.0	120
10	Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN. <i>Clinical Cancer Research</i> , 2017, 23, 2442-2450.	7.0	102
11	Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes. <i>Annals of Thoracic Surgery</i> , 2008, 86, 1632-1639.	1.3	96
12	Treatment of Recurrent Squamous Cell Carcinoma of the Skin With Cetuximab. <i>Archives of Dermatology</i> , 2007, 143, 889-92.	1.4	92
13	Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study. <i>Journal of Oncology Practice</i> , 2018, 14, e176-e185.	2.5	74
14	A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 836-847.	2.6	63
15	Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 145-151.	1.1	48
16	<i>MYCN</i> drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity. <i>Genes and Development</i> , 2020, 34, 1210-1226.	5.9	46
17	Estrogen Signaling in Lung Cancer: An Opportunity for Novel Therapy. <i>Cancers</i> , 2012, 4, 969-988.	3.7	45
18	Occult Primary. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1358-1395.	4.9	41

#	ARTICLE	IF	CITATIONS
19	Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. <i>Journal of Thoracic Oncology</i> , 2018, 13, 649-659.	1.1	35
20	An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). <i>Lung Cancer</i> , 2017, 104, 126-130.	2.0	33
21	Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. , 2020, 8, e001009.		30
22	Phase 2 Study of Erlotinib in Combination With Alectinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 34-42.e2.	2.6	29
23	Maintenance Chemotherapy in Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 815-821.	4.9	27
24	Occult Primary, Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 969-974.	4.9	27
25	A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2012, 12, 449.	2.6	26
26	Radiation-Induced Myelopathy. <i>Archives of Neurology</i> , 2011, 68, 1608.	4.5	25
27	Intradural intramedullary spinal cord metastasis due to mesothelioma. <i>Journal of Neuro-Oncology</i> , 2010, 97, 133-136.	2.9	24
28	Antagonism of Platelet-Derived Growth Factor Receptor in Non-Small Cell Lung Cancer: Rationale and Investigations. <i>Clinical Cancer Research</i> , 2007, 13, 4632s-4636s.	7.0	23
29	Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. <i>Oncologist</i> , 2014, 19, 175-176.	3.7	21
30	Detection of HPV in oral rinse samples from OPSCC and non-OPSCC patients. <i>BMC Oral Health</i> , 2015, 15, 126.	2.3	17
31	The Pseudocavitation Sign of Lung Adenocarcinoma. <i>Journal of Thoracic Imaging</i> , 2015, 30, 308-313.	1.5	17
32	Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. <i>Head and Neck</i> , 2018, 40, 584-589.	2.0	13
33	Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience. <i>Head and Neck</i> , 2016, 38, 1318-1323.	2.0	12
34	Value-Based Care in Lung Cancer. <i>Oncologist</i> , 2016, 21, 903-906.	3.7	12
35	EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers. <i>Journal of Thoracic Oncology</i> , 2013, 8, e6-e7.	1.1	11
36	Performance status (<sc>PS</sc>) as a predictor of poor response to immune checkpoint inhibitors (<sc>ICI</sc>) in recurrent/metastatic head and neck cancer (<sc>RMHNSCC</sc>) patients. <i>Cancer Medicine</i> , 2022, 11, 4104-4111.	2.8	11

#	ARTICLE	IF	CITATIONS
37	Spontaneous Regression of Non-Small-Cell Lung Cancer in AIDS After Immune Reconstitution. <i>Journal of Thoracic Oncology</i> , 2015, 10, e1-e2.	1.1	10
38	Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With <i>IKZF3</i> Deletion and <i>TP53</i> Mutation. <i>American Journal of Clinical Pathology</i> , 2015, 144, 263-270.	0.7	10
39	Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2017, 127, 1583-1588.	2.0	8
40	Is There a Role for Whole Brain Radiotherapy in the Treatment of Leptomeningeal Metastases?. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1204.	1.1	7
41	Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial. <i>Cancer</i> , 2018, 124, 2841-2849.	4.1	7
42	Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome. <i>BMC Cancer</i> , 2019, 19, 70.	2.6	6
43	A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101541.	0.4	5
44	Pregnancy Screening in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 99-103.	4.9	4
45	Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 523-530.	2.6	4
46	Impact of Diagnostic Delays on Lung Cancer Survival Outcomes: A Population Study of the US SEER-Medicare Database. <i>JCO Oncology Practice</i> , 2022, 18, e877-e885.	2.9	4
47	Cancer pain: Perspectives of a medical oncologist. <i>Current Pain and Headache Reports</i> , 2008, 12, 270-276.	2.9	3
48	Effect of Clinical Trial Participation on Costs to Payers in Metastatic Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1225-e1234.	2.9	3
49	Aldosterone-Secreting Adrenocortical Carcinoma Presenting With Cardiac Arrest. <i>Journal of the Endocrine Society</i> , 2019, 3, 1678-1681.	0.2	2
50	Occult Primary. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 1026.	4.9	2
51	A 66-Year-Old Woman With Newly Diagnosed Oligometastatic Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 297-301.	4.9	1
52	Evaluation of Failure Patterns Using Trimodality in Non-Small Cell Lung Cancer. <i>World Journal of Oncology</i> , 2011, 2, 64-69.	1.5	1
53	Timing of postoperative radiation therapy and survival in resected salivary gland cancers: Long-term results from a single institution. <i>Oral Oncology</i> , 2021, 123, 105626.	1.5	1
54	Sarcoidosis Presenting as Isolated Anasarca and Hypercalcemia. <i>American Journal of Medicine</i> , 2019, 132, e13-e14.	1.5	0

#	ARTICLE	IF	CITATIONS
55	A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100416.	1.7	0
56	Adaptive Fluorodeoxyglucose-Positron Emission Tomography Based Chemotherapy Selection for Metastatic Non-small Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e18804.	0.5	0
57	High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Palliative Medicine</i> , 2021, , .	1.1	0